1.. INTRODUCTION {#sec1}
================

Central neurocytomas (CNCs) are a rare benign neuroectodermal, intraventricular tumors consisting 0.25--0.5% of primary brain lesions in young adults, commonly found in the supratentorial ventricles. Extra ventricular neurocytoma location is exceptionally rare \[[@ref1]-[@ref3]\]. According to the World Health Organization (WHO) 2016, Categorized as grade II \[[@ref4]\]. Central neurocytomas even though are benign nevertheless recurrence can be perceived. Central neurocytomas mandates a surgical intervention with a gross-total resection which is modality of paramount currently. Anaplastic CNCs can be rarely seen \[[@ref5], [@ref6]\].

2.. AIM {#sec2}
=======

This review aims to highpoint the entity of central neurocytoma in patients managed by our department and the unique surgical considerations, additionally, to review the epidemiology and demographics in patients treated in our institution, also to highlight the new horizons of management flourishing nowadays.

3.. PATIENTS AND METHODS {#sec3}
========================

This retrospective analysis was carried out by reviewing all consecutives patients and their medical records in whom central neurocytoma had been diagnosed and managed at King Hussein medical center (KHMC). Patient's reports were retrieved from the electronic hospital database during a 14-year period (2004--2018). Diagnosis was based on clinical symptoms, radiological findings and confirmed by histopathological tests. All patients' data were recorded including the comprehensive history encompassing patient demographics (age and gender), presenting complaints, clinical and neurological findings, intraoperative findings, pre-and post-operative imaging, histopathological diagnosis and post-operative complications. The mean clinical follow up period was 57 months. One of two surgical approaches (transcortical and transcallosal) was utilized for accessing and resecting the tumors depending on the location, size and direction of extension of the tumor and regardless of the degree of ventricular dilatation. If the tumor was midline with no extension into the ventricular horns the transcallosal approach was used, while if the tumor was eccentrically placed or extended into a ventricular horn the transcortical approach was used. The study was approved by the Royal Medical Services Institutional ethics committee (6/3/2020). As this study is a retrospective chart analysis, hence the prerequisite for consent was waived.

###### Demographic data analyzed

                                           Age    Sex      Approach          Biopsy results                          Resection extent
  ---------------------------------------- ------ -------- ----------------- --------------------------------------- --------------------------------
  1                                        58 y   Male     Transcortical     WHO II with Anaplastic transformation   Subtotal - Conventional RXT
  2                                        20 y   Female   Transcortical     WHO II                                  Gross Total Resection
  3                                        30 y   Female   Transcallosal     WHO II                                  Gross Total Resection
  4                                        31y    Female   Transcallosal     WHO II                                  Gross Total Resection
  5                                        27y    Female   Transcallosal     WHO II                                  Gross Total Resection
  6                                        27y    Male     Transcallosal     WHO II                                  Gross Total Resection
  7                                        35y    Male     Posterior Fossa   Cerebellar liponeurocytoma              Gross Total Resection
  8                                        40y    Female   Transcortical     WHO II with atypical features           Gross Total Resection
  9                                        35y    Female   Transcallosal     WHO II                                  Gross Total Resection
  10                                       18y    Female   Transcallosal     WHO II                                  Gross Total Resection
  11                                       36y    Male     Transcallosal     WHO II                                  Gross Total Resection
  12                                       43y    Male     Transcallosal     WHO II                                  Gross Total Resection
  13                                       23y    Female   Transcortical     WHO II                                  Gross Total Resection
  14                                       23y    Male     Transcallosal     WHO II                                  Gross Total Resection
  15                                       22y    Female   Transcortical     WHO II                                  Gross Total Resection
  16                                       23y    Male     Transcortical+    WHO II with atypical features           Gross Total Resection with RXT
  17                                       21y    Female   Transcallosal     WHO II                                  Gross Total Resection
  18                                       20y    Male     Transcortical     WHO II                                  Gross Total Resection
  19                                       20y    Female   Transcortical     WHO II                                  Gross Total Resection
  20                                       30y    Male     Transcortical     WHO II with atypical features           Subtotal - Conventional RXT
  21                                       28y    Female   Transcallosal     WHO II                                  Gross Total Resection
  22                                       23y    Male     Transcortical+    WHO II with atypical features           Subtotal -- Conventional RXT
  23                                       42y    Male     Transcortical     WHO II with atypical features           Subtotal -- Conventional RXT
  24                                       25y    Male     Transcortical     WHO II                                  Gross Total Resection
  25                                       21y    Female   Transcortical     WHO II                                  Gross Total Resection
  26                                       18y    Female   Transcortical     WHO II                                  Gross Total Resection
  27                                       30y    Female   Transcallosal     WHO II with atypical features           Subtotal -- Gamma Knife
  28                                       31y    Female   Transcortical     WHO II with anaplastic transformation   Subtotal -- Conventional RXT
  29                                       23y    Female   Transcortical     WHO II                                  Gross Total Resection
  30                                       32y    Female   Transcortical     WHO II Extraventricular                 Gross Total Resection
  31                                       24y    Male     Transcallosal     WHO II                                  Gross Total Resection
                                           27y    Male     Transcallosal     WHO II                                  Gross Total Resection
  33                                       57y    Female   Transcortical     WHO II Extraventricular                 Gross Total Resection
  \+ Patients underwent 2-stages surgery                                                                             

4.. RESULTS {#sec4}
===========

Our cohort consisted of 33-adult patients operated for pathologically confirmed intracranial neurocytoma. Of the final population 42.42% of the patients were males, analysis revealed female to male ratio of 1.36:1. Mean age at diagnosis was 29.48±9.78 years, ranging from 18-58 years \[[Table.1](#table1){ref-type="table"}\]. The mean clinical follow up after clinical diagnosis was 57 months (ranging between 34-168 months). Tumor locations were intraventricular in 31 cases and only two case were extra-ventricular.

Clinically, most common presenting symptoms were headache and blurring of vision (90.91%) which were observed in 30-patients, papilledema was found in 20-patients (60.61%) and one patient presented with diplopia. No significant motor weakness was noted at presentation although many of the tumors were considerably large in size at presentation. Patients were scheduled for elective surgery within one week of presentation, one patient required ventricular shunt placement preoperatively due to the presence of severely dilated ventricles and decreased level of consciousness.

Approximately half of the cases were operated using a transcortical approach and the other half using a transcallosal approach, the decision of the approach was undertaken on the basis of location of the tumor from the midline and not based on dilation of ventricles as mentioned earlier. In 27-cases gross total resection was achieved, while in 6-cases only subtotal resection could be achieved. Study showed 25-cases with typical histopathological features and in 6- cases presented with atypical features, also 2-cases had anaplastic transformation. One case revealed a cerebellar central liponeurocytoma and one case was right frontal extra-ventricular. In two cases, intra-operative bleeding made the dissection difficult and the operations achieve maximal safe resection with post-operative follow up for growth in order to determine the need for a second stage operation. External ventricular drain was needed in twelve cases at the end of the operation due to excessive bleeding encountered intraoperatively and in order to avoid hydrocephalus, of the 12-cases with the external ventricular drainage only five cases needed a ventriculo-peritoneal shunt due to the presence of hydrocephalus after trial of external ventricular drainage closure. Six cases had atypical central neurocytomas, who after gross total resection received adjuvant radiotherapy. Only one patient developed recurrence. Two patients had 2-stages surgery ([Fig.1](#fig1){ref-type="fig"})

![Radiological Images of a Patient underwent 2-stages surgery, a) Pre-operative images, b) Radiological images after the first surgery, c) Post-operative images after the second surgery.](AIM-28-146-g001){#fig1}

![a-c from low to high power view, showing monotonous bland cells with modest cytoplasm, often empty appearing "halo" resembling oligodendroglioma, salt and pepper chromatin, embedded in eosinophilic fibrillar matrix with rare Homer Wright rosettes](AIM-28-146-g002){#fig2}

5.. DISCUSSION {#sec5}
==============

Central neurocytomas are neuroectodermal tumors arising mainly from the septum pellucidum in the lateral ventricle, that originate from bi-potential progenitor cells in the periventricular matrix, where there are many stem or precursor cells in the sub-ependymal or sub-ventricular zone. Reports showed proofs for both glial and neuronal differentiation in many tumors \[[@ref4], [@ref7], [@ref8]\]. Macroscopically central neurocytomas have a well circumscribed and demarcated border, a greyish lobulated nodular mass with highly vascularized regions and sometimes show areas of hemorrhage, the gritty feel experienced by surgeons is attributed to the presence of micro-calcifications. On light microscope the tumors typically consist of small to medium sized uniform neuronally differentiated and mitotically inactive cells with round nuclei, stippled chromatin and inconspicuous nucleoli, scant cytoplasm intermingled with areas of anuclear and less dense fibrillary matrix, with polygonal cells and perinuclear " halos" that resemble those seen in oligodendroglioma ([Fig. 2](#fig2){ref-type="fig"}), making oligodendrogliomas the main micro morphological differential diagnosis \[[@ref9]-[@ref11]\]. Thus, cultured cells could be subdivided into many types; a neuronal type with positive staining for filament proteins; secretory granules, with an undifferentiated cell type plus an increased nuclear-cytoplasm ratio; and astrocytic small round astrocytic cell with intermediate filaments that stain positive for GFAP 27. Importantly, IDH mutations and 1p19q co-deletion are absent --which are characteristic diagnostic parameters of oligodendrogliomas \[[@ref12]\]. Central neurocytomas defined histopathologicaly 'atypical' when anaplastic features of increased mitotic activity, microvascular proliferation and necrosis observed, any central neurocytomas showing a Ki-67 proliferation index of ≥2 or 3% is reported atypical \[[@ref9]\]. Increased rates of recurrence are associated with high mitotic count of ≥3 % \[[@ref5], [@ref13]-[@ref15]\]. Our study revealed six cases of atypical CNCs.

![showing a brain CT scan for a patients presented with acute hydrocephalus, patient underwent bilateral vetriculoperitoneal shunt insertion, then prepared for elective surgery.](AIM-28-146-g003){#fig3}

![Showing the radiological examination and findings in case on central neurocytoma: a) axial brain CT shows large hyper-dense soft tissue mass contains peripheral cystic consonants in the body of the RT lateral ventricle, the lesion shows no calcifications; b) axial T1 : the lesion appears isointense with central small hemorrhagic component, the lesion is attached to thseptum pellucidum which appears bowed to the left side; c) axial T2 : heterogeneously isointense with peripheral cystic components giving the lesion bubbly appearance, the lesion contains small signal void peripherally. Significant dilatation of thelateral ventricle with minimal transepenymal edema; d & e) diffusion study and ADC map shows mild restriction with low ADC value; f) axial T1 post contrast: mild hetero-genous contrast enhancement. The lesion abuts the head of the RT caudated nucleus with no extra-ventricular extension.](AIM-28-146-g004){#fig4}

Patients with central neurocytomas originate in the ventricular system or extra-ventricular present with clinical signs and symptoms that allied to one of two general classes: Those that result from the tumor mass effects, and those attributable to obstructive hydrocephalus. The presence of a mass in the region immediately neighboring the foramen of Monro results in increased intracranial pressure and compression on surrounding structures. However, the neurocytomas might found in an extra-ventricular location (cerebral, cerebellar, brainstem, or spinal parenchyma) with correlated clinical presentation. Radiologically, tumor appears on brain CT hypodense compared to white matter, with areas of punctate calcifications and cysts especially in the larger tumors, and rarely hemorrhage within it, post contrast shows mild-to-moderate contrast enhancement ([Fig. 3](#fig3){ref-type="fig"}). While, on magnetic resonance imaging, it appears heterogeneous and isointense to grey matter on T1WI with mild to moderate contrast enhancement. They are hyper intense on T2WI and FLAIR sequences with prominent flow voids and cystic areas that give central neurocytoma a bubbly appearance. Calcifications and hemorrhage could be identified on the GE/SWI sequences ([Fig. 4](#fig4){ref-type="fig"}). Strong choline peaks are evident on MR spectroscopy and some studies report the presence of a glycine peak \[[@ref16]\]. In our review 30-cases presented with signs and symptoms of increased intracranial pressure, the other three cases discovered incidentally. Literature showed about 70% of affected individuals are between the age group of 20 and 40 years, No racial profile was identified and no gender predilection has been described, with a male-to-female ratio of 1.02:1\[[@ref17]\]. In our analysis patients ages were between 18-years and 58-years, mean age at diagnosis was 29.48±9.78 years. Also we identified 2-cases of extra-ventricular neurocytomas ([Fig. 5](#fig5){ref-type="fig"}). Of the final cohort 42.42% of the patients were males, with a female-to-male ratio of 1.36:1.

![Showing a case of extra-ventricular neurocytoma: a) axial brain CT: Right inferior frontal cystic lesion with hyperdense hemorrhagic solid component centrally and peripheral calcifications mimicking oligodendroglioma; b) axial T1 precontrast: the intraparenchymal lesion appears hypointense compressing the frontal horn of the right lateral ventricle, with shift of midline structures to the left; c) Axial T2: heterogenous hypointense small solid nodule surrounded by large cystic component; d) Axial FLAIR: The lesion is surrounded by moderate peritumoral vasogenic edema; e) SWI: blooming artefact in the central solid component suggestive of internal hemorrhage; f) T1 axial post contrast demonstrate heterogenous mild enhancement in the solid component.](AIM-28-146-g005){#fig5}

![Showing the Axial cut for a patient underwent gross total resection of central neurocytoma, a) pre-operative image, b) post-operative image, demonstrating a V-P shunt applied for post-operative hydrocephalus.](AIM-28-146-g006){#fig6}

The pillar of central neurocytoma treatment is to achieve total and safe resection when feasible, which can be conducted either through the available approach: transcallosal or transcortical, however, the approach has to be tailored according to anatomy and severity of hydrocephalus. The profits and jeopardies of each approach such as post-operative seizures and neuropsychological consequences should be considered during decision-making \[[@ref18]\]. According to our analysis twenty-seven patients underwent gross total resection (GTR) and six patients underwent subtotal resection (STR). The surgical corridors utilized to tackle CNs in this study included a transcortical approach in 18-cases and an interhemispheric transcallosal approach in 14-cases. There were no differences in terms of functional outcomes or initial extent of resection according to the surgical approach used. In terms of complications encountered; analysis showed Infection in 2-cases, transient Hemiparesis in 6-cases in which recovery achieved within 1 week -- 6 months. Post-operative hydrocephalus managed in 5-cases by inserting a permanent ventriculo-peritoneal shunt ([Fig. 6](#fig6){ref-type="fig"}). While, behavioral changes and transient memory loss noticed in 3-cases and 7-cases respectively. Mortality reported in 2-cases. The literature advocate that the use of adjuvant radiotherapy in not indicated after gross total resection, however, it can be offered for residual/recurrent tumor, though it remains matter of controversy \[[@ref1], [@ref8], [@ref14], [@ref15], [@ref18], [@ref19]\]. In our center we follow the same guidelines.

Central neurocytoma aggregate data after several reports in literature will continue to shape treatment paradigms. Central neurocytoma still enigmatic in many terms: origin, histopathological diagnosis and adjuvant therapies needed. The advances in molecular field; radiological advances and emerging chemotherapies in the evolving genomic landscape of cancer merits additional actionable therapeutic targets and further study.

6.. CONCLUSION {#sec6}
==============

Central neurocytoma is a rare benign neuroepithelial tumor of unknown cells of origin, that usually demonstrates in a relatively young population, increased intracranial pressure due to the slow increase in size of the tumor are the cardinal clinical presentation. The foremost treatment goal is to achieve early safe surgical excision of the tumor and the route of approach should be tailored according to the location of the tumor from midline and associated hydrocephalus, staged surgeries may be needed with different approaches utilized in very large tumors extending in the anteroposterior dimensions. External ventricular drainage is advocated post-operatively; especially if there was excessive bleeding into the ventricular system during removal of the tumor. Safe maximal resection is the rule and total resection showed promising results in establishing cure and preventing recurrence. Regular follow-up of the patient with imaging is needed to determine if there is recurrence in which case radiotherapy could be instituted if another surgery is not feasible to remove the recurrence or residual mass. The flourishing treatment modalities seem to be promising.
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